Sagimet Biosciences Inc.
SGMT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SGMT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SGMT
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing proprietary fatty acid synthase (FASN) inhibitors for non-alcoholic steatohepatitis (NASH) and other liver diseases, with no approved products and a focus on advancing its lead candidate denifanstat through Phase 2 and Phase 3 trials.
Key risk: No approved products
BioSniper Score
Based on 6 of 6 signals
Market Cap
$655.8M
Cash Runway
64.2 moLead Asset
denifanstat (Phase 1)Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 6 clinical trials · 4 catalysts for Sagimet Biosciences Inc..
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing proprietary fatty acid synthase (FASN) inhibitors for non-alcoholic steatohepatitis (NASH) and other liver diseases, with no approved products and a focus on advancing its lead candidate denifanstat through Phase 2 and Phase 3 trials.
- Sagimet is a clinical-stage company with no approved products and no revenue from product sales; its lead candidate is denifanstat, a FASN inhibitor for NASH/liver diseases [sec_mda].
- As of June 30, 2026, the company reported cash and equivalents of $165.9M, net income of -$14.0M, and shareholders' equity of $111.4M [sec].
- The company has established an at-the-market offering (2025 ATM) for up to $75.0M in shares, with no sales through December 31, 2025 [sec_mda · as of 2026-03-11].
- Sagimet has not generated any revenue from product sales and expects to continue incurring significant expenses as it advances its pipeline through preclinical and clinical trials [sec_mda · as of 2025-08-13].
What works
- Sagimet has a cash runway of $165.9M as of June 30, 2026, which may support ongoing clinical development without near-term financing needs [sec].
- The company's lead candidate denifanstat is in Phase 2 and Phase 3 trials for NASH, a large unmet medical need with no FDA-approved therapies [sec_mda].
- Sagimet has a proprietary FASN inhibitor platform that could be applied to multiple metabolic and fibrotic diseases, providing pipeline optionality [sec_mda · as of 2025-11-13].
What to weigh
- Sagimet has no approved products and has never generated revenue from product sales; its future depends entirely on successful clinical development and regulatory approval [sec_mda · as of 2025-08-13].
- The company has a history of net losses, with a net loss of $14.0M in the most recent quarter (June 30, 2026) and accumulated deficits from prior periods [sec].
- Clinical development of FASN inhibitors is high-risk; denifanstat's Phase 2 and Phase 3 trials may fail to meet endpoints, leading to significant value loss [sec_mda].
- Sagimet's cash position of $165.9M may be insufficient to complete all planned trials without additional financing, which could dilute existing shareholders [sec_mda · as of 2026-03-11].
From the filings
Quoted directly from source documents.
Sagimet has no approved products and no revenue from product sales.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · August 13, 2025
Sagimet's cash position as of June 30, 2025 was $135.5 million.
“As of June 30, 2025, we had cash, cash equivalents and marketable securities of $135.5 million.”
SEC MD&A · August 13, 2025
Sagimet has an at-the-market offering for up to $75.0 million.
“we entered into a Sales Agreement with Leerink Partners LLC to establish an at-the-market offering (2025 ATM Offering) through which we may sell, from time to time at our sole discretion, up to $75.0 million shares of our Series A common stock.”
SEC MD&A · March 11, 2026
Sagimet's lead candidate is denifanstat, a FASN inhibitor for NASH.
“developing our pipeline of proprietary FASN inhibitors and other drug targets”
SEC MD&A · November 13, 2025
Catalyst timeline
- 2026-12-31 · Phase2_Topline · tvb-3567 — Phase 2 Readout: tvb-3567 — Topline data from a Phase 2 trial of tvb-3567 (denifanstat) will provide initial efficacy and safety signals in the target indication.
- 2026-12-31 · Phase2_Topline — Phase 2 Readout: Liver Treatment — Topline data from a Phase 2 trial for a liver treatment candidate will inform further development decisions.
- 2027-06-01 · Phase3_Topline · denifanstat — Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of — Topline results from a pivotal Phase 3 trial of denifanstat in NASH will be a key value inflection point.
- 2030-12-01 · Phase3_Topline · denifanstat — Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of — Topline results from a second Phase 3 trial of denifanstat will provide additional efficacy and safety data for regulatory submission.
Risks & what to watch (4)›
Key risks
- No approved products — Sagimet has no approved products and no revenue from product sales; all candidates are in clinical or preclinical stages [sec_mda].
- Clinical trial failure risk — Denifanstat's Phase 2 and Phase 3 trials may fail to meet efficacy or safety endpoints, leading to program discontinuation [sec_mda].
- Cash runway uncertainty — Cash of $165.9M (June 30, 2026) may not be sufficient to complete all trials without additional financing [sec].
- Regulatory hurdles — No FDA-approved FASN inhibitor exists; regulatory pathway for NASH is evolving and uncertain [sec_mda].
What to watch
- Phase 2 topline data for denifanstat (tvb-3567) expected by end of 2026 [catalyst].
- Phase 3 topline data for denifanstat in NASH expected in 2027 and 2030 [catalyst].
- Cash burn rate and any additional financing activities, including use of the $75M ATM facility [sec_mda · as of 2026-03-11].
- Regulatory updates from FDA on NASH endpoints and potential breakthrough therapy designation [sec_mda].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Sagimet Biosciences Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Sagimet Biosciences Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
64.2 months
D/E 0.03 · 0% dilution
Lead: Phase 1
2 candidates
4 upcoming, next in ~123d
0 buys · 5 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
86
Total value held
$71.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,197,838 | $11.5M |
| marshall wace, llp | 966,253 | $5.0M |
| baker bros. advisors lp | 952,996 | $5.0M |
| affinity asset advisors, llc | 868,020 | $4.5M |
| millennium management llc | 862,303 | $4.5M |
| blackrock, inc. | 799,943 | $4.2M |
| hhlr advisors, ltd. | 724,800 | $3.8M |
| renaissance technologies llc | 625,469 | $3.3M |
| d. e. shaw & co., inc. | 411,570 | $2.2M |
| blue owl capital holdings lp | 333,877 | $1.7M |
Showing top 10 of 86 institutional holders of Sagimet Biosciences Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 12.1%
- Days to cover
- 9.3
- Shares short
- 3,598,600
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SGMT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Sagimet Biosciences Inc.?
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing proprietary fatty acid synthase (FASN) inhibitors for non-alcoholic steatohepatitis (NASH) and other liver diseases, with no approved products and a focus on advancing its lead candidate denifanstat through Phase 2 and Phase 3 trials.
What is Sagimet Biosciences Inc.'s lead drug candidate?
Sagimet Biosciences Inc.'s most advanced tracked candidate is denifanstat (Phase 1) for Healthy; MASH; MASLD.
What is Sagimet Biosciences Inc.'s next catalyst?
Sagimet Biosciences Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: tvb-3567" — expected December 31, 2026.
Who is the CEO of Sagimet Biosciences Inc.?
Mr. David A. Happel is the chief executive officer of Sagimet Biosciences Inc. (SGMT).
Where is Sagimet Biosciences Inc. headquartered?
Sagimet Biosciences Inc. (SGMT) is headquartered in San Mateo, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.